依达拉奉对急性心肌梗死溶栓后肌钙蛋白I和C-反应蛋白的影响  

Effect of edaravone on troponin I and C-reactive protein in acute myocardial infarction after thrombolysis

作　　者：沈桂彬[1] 

机构地区：[1]郑州市第七人民医院急诊科,450016

出　　处：《中国实用医刊》2013年第22期18-19,共2页Chinese Journal of Practical Medicine

摘　　要：目的探讨依达拉奉对急性心肌梗死（AMI）溶栓后肌钙蛋白I和C-反应蛋白的影响。方法将60例AMI患者随机分为治疗组30例与对照组30例。观察两组再灌注后心律失常发生率，测定溶栓后2、24h的磷酸肌酸激酶同工酶（CK—MB）和心肌肌钙蛋白I（cTnI），溶栓后24h、48h、7d的C．反应蛋白。结果两组治疗后24h的CK—MB和2、24h的cTnI及治疗后48h、7d的C-反应蛋白比较差异有统计学意义（P〈0．05）。结论急性心肌梗死时在常规治疗基础上加用依达拉奉，可明显减轻再灌注损伤，改善AMI患者的生存率及预后。Objective To investigate the effect of edaravone on troponin I and C-reactive protein in acute myocardial infarction （AMI） after thrombolysis. Methods Sixty cases of AMI patients were ran- domly divided into treatment group （n = 30） and control group （ n = 30）. The incidence of reperfusion ar- rhythmias was observed, and the levels of CK-MB and cardiac troponin I（cTnI） at 2 hours, 24 havs, and the levels of C-reactive protein at 24 h, 48 h, 7 d were measured. Results After treatment, there were significantly differences in 24 hour of CK-MB, 2 hours and 24 hours of eTnI and 48 hour, 7 days of C-reac- tive protein levels between the two groups （P 〈 0. 05） . Conclusions Application of edaravone on the basis of conventional therapy, can significantly reduce reperfusion injury in acute myocardial infarction, improve the survival rate and prognosis of patients with AMI.

关 键 词：依达拉奉 急性心肌梗死 肌钙蛋白I C-反应蛋白 再灌注损伤 

分 类 号：R542.22[医药卫生—心血管疾病]